Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 10;11(11):e007697. doi: 10.1136/jitc-2023-007697

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Treatment affects circulating myeloid cell numbers and the mMDSC/DC ratio. (A) Treatment-induced changes in specific cell populations, defined and described in figure 4, were further analyzed. Populations 1, 3, 5, and 6 showed the largest and most significant change when frequencies between pretreatment versus second chemotherapy+1 week samples (left panel), and also when samples from 1 vs 2 weeks after the second chemotherapy (right panel), were compared using OMIQ and edgeR. (B) Frequencies of sequential blood samples show a transient and significant decrease in populations 1, 3, 5, and a near significant decrease in population 6 from baseline, (C) Baseline frequencies of population 1, 2 and 3 were depicted for patients with a shorter and longer than median OS, respectively. Given p values according to Mann-Whitney U test. (D) Baseline mMDCS/DC ratios were calculated and compared with ratios previously determined and described for ovarian cancer patients included in the PITCH or CHIP trial.10 In brief, CD3⁻CD19⁻CD56^-HLA-DR^−/lowCD14⁺CD15⁻ (mMDSC) and CD3⁻CD19⁻CD56⁻HLA-DR⁺CD14⁻CD11c⁺ (DC) were determined as percentage of total CD45⁺ cells after multicolor flowcytometry (as described in figure 4) and ratios of these cell populations are plotted for evaluated patients in the PITCH-CHIP trial (n=36) and OVACURE trial (n=12). (E) Kaplan-Meier plots show the survival of patients divided in patients with an mMDSC/DC ratio above (dotted line) and below (solid line) median. (F) mMDSC and DC frequencies were determined in sequential blood samples obtained at baseline and during treatment and show a significant but transient, treatment-induced reduction in mMDSC/DC ratio at 1 week after the second chemotherapy cycle.*p<0.05, **p<0.01, ***p<0.001 by Kruskal-Wallis with Dunn’s correction for multiple comparisons. DC, dendritic cell; MDSC, myeloid-derived suppressor cells; OS, overall survival.